Histologic scoring systems specific for primary sclerosing cholangitis (PSC) are not validated. We recently determined the applicability and prognostic value of three histological scoring systems in a single PSC cohort. The aim of this study was to validate their prognostic use and reproducibility across a multicenter PSC cohort. Liver biopsies from PSC patients were collected from seven European institutions. Histologic scoring was performed using the Nakanuma, Ishak, and Ludwig scoring systems. Biopsies were independently scored by six liver pathologists for interobserver agreement. The prognostic value of clinical, biochemical, and all three histologic scoring systems on predicting composite endpoints 1 (PSCrelated death and liver transplantation), 2 (liver transplantation), and 3 (liver-related events), was assessed using univariable and multivariable Cox proportional hazards modeling. A total of 119 PSC patients were identified, and the median follow-up was 142 months. During follow-up, 31 patients died (20 PSC-related deaths), 31 patients underwent liver transplantation, and 35 patients experienced one or more liver-related events. All three staging systems were independent predictors of endpoints 2 and 3 (Nakanuma system: hazard ratio [ . Only the Nakanuma staging system was independently associated with endpoint 1: HR, 2.14 (95% CI, 1.22-3.77). Interobserver agreement was moderate for Nakanuma stage (j 5 0.56) and substantial for Nakanuma component fibrosis (j 5 0.67), Ishak stage (j 5 0.64), and Ludwig stage (j 5 0.62). Conclusion: We confirm the independent prognostic value and demonstrate for the first time the reproducibility of staging disease progression in PSC using the Nakanuma, Ishak, and Ludwig staging systems. The Nakanuma staging system-incorporating features of chronic biliary disease-again showed the strongest predictive value. (HEPATOLOGY 2017;65:907-919).
Histologic scoring systems specific for primary sclerosing cholangitis (PSC) are not validated. We recently determined the applicability and prognostic value of three histological scoring systems in a single PSC cohort. The aim of this study was to validate their prognostic use and reproducibility across a multicenter PSC cohort. Liver biopsies from PSC patients were collected from seven European institutions. Histologic scoring was performed using the Nakanuma, Ishak, and Ludwig scoring systems. Biopsies were independently scored by six liver pathologists for interobserver agreement. The prognostic value of clinical, biochemical, and all three histologic scoring systems on predicting composite endpoints 1 (PSCrelated death and liver transplantation), 2 (liver transplantation), and 3 (liver-related events), was assessed using univariable and multivariable Cox proportional hazards modeling. A total of 119 PSC patients were identified, and the median follow-up was 142 months. During follow-up, 31 patients died (20 PSC-related deaths), 31 patients underwent liver transplantation, and 35 patients experienced one or more liver-related events. All three staging systems were independent predictors of endpoints 2 and 3 (Nakanuma system: hazard ratio [ 3) . Only the Nakanuma staging system was independently associated with endpoint 1: HR, 2.14 (95% CI, 1.22-3.77). Interobserver agreement was moderate for Nakanuma stage (j 5 0.56) and substantial for Nakanuma component fibrosis (j 5 0.67), Ishak stage (j 5 0.64), and Ludwig stage (j 5 0.62). Conclusion: We confirm the independent prognostic value and demonstrate for the first time the reproducibility of staging disease progression in PSC using the Nakanuma, Ishak, and Ludwig staging systems. The Nakanuma staging system-incorporating features of chronic biliary disease-again showed the strongest predictive value. (HEPATOLOGY 2017;65:907-919). P rimary sclerosing cholangitis (PSC) is an idiopathic cholestatic liver disease affecting the intra-and/or extrahepatic bile ducts.
(1) Chronic inflammation induces formation of fibrotic strictures, interspersed with dilatations, resulting in a typical "beaded" appearance when visualizing the PSC bile ducts on a cholangiogram.
Liver biopsy is no longer routinely performed to establish a diagnosis of PSC. (2, 3) However, there are still some circumstances in which the assessment of liver histology is important diagnostically, such as the suspicion of small duct PSC or PSC/autoimmune hepatitis (AIH) overlap syndrome. In addition to its diagnostic purpose, histological assessment of disease severity may also be useful to stratify clinical outcomes in autoimmune and cholestatic liver diseases, particularly when determining entry into clinical trials, ruling out comorbidities, and evaluating the efficacy of prospective therapeutic interventions. (4) Histologically, the characteristic fibrosing duct lesions of PSC mainly involve medium-sized (septal) ducts and are thus infrequently seen in needle biopsy specimens. (5) Varying degrees of portal and periportal inflammation are commonly present, particularly during the early stages of PSC, and may be associated with bile duct inflammation. As the disease progresses, there is loss of small and medium-sized ducts (ductopenia) and the development of secondary changes related to chronic cholestasis including ductular reaction and the accumulation of copper binding protein in periportal hepatocytes. (6) These changes are associated with the development of progressive periportal fibrosis, ultimately leading to the development of biliary cirrhosis. (6) In the absence of a validated histologic scoring system specifically designed to assess disease severity in PSC, we recently assessed the applicability and prognostic value of three histologic scoring systems, designed primarily to assess disease severity in chronic hepatitis (Ishak system) and primary biliary cholangitis (PBC) (Ludwig and Nakanuma systems), across a group of patients with PSC. (7) Staging by each of these three scoring systems was shown to be strongly associated with disease progression in PSC. (7) However, this was a single-center study with a relatively small sample size that included only biopsies taken at the time of diagnosis. Furthermore, although all three histologic scoring systems are being applied in clinical practice, their reproducibility for PSC is unknown.
In the present study, we attempted to validate the prognostic value and reproducibility of liver histology using the three previously evaluated scoring systems in a wellcharacterized multicenter external cohort of PSC patients.
Patients and Methods

PATIENTS AND TISSUE PREPARATION
For this multicenter cohort study, PSC patients from seven centers in six European countries were included: Helsinki University Hospital, Finland; University Hospital Heidelberg, Germany; Queen Elizabeth Hospital, United Kingdom; Rigshospitalet, Denmark; Erasmus University Medical Center, Netherlands; Hôpital Saint Antoine, France; and John Radcliffe Hospital, United Kingdom. PSC diagnosis was established according to the European Association for the Study of the Liver guidelines. (2) A diagnosis of PSC/AIH-overlap syndrome was made in keeping with expertise of the contributing center.
To ensure adequate follow-up time, PSC patients with liver biopsies taken at least 10 years ago were included, and biopsy material was requested from the archives by liver pathologists in the participating centers. Biopsies taken between 1980 and 2006 were included. The original hematoxylin and eosin, connective tissue, and orcein-stained sections were collected and the quality of the staining was checked. In those cases where staining had faded over time, additional immunohistochemical stainings were performed. In the event that the pathology laboratory of the participating center did not perform orcein histochemistry, additional orcein staining was performed by the laboratory of S.H. (Birmingham, UK). Clinical data were collected retrospectively from patients' records with reference to patient demographics, medication use, liver biochemistry at time of diagnosis (61 month), liverrelated events (variceal bleeding, ascites, splenomegaly, and hepatic encephalopathy), and the occurrence of cholangiocarcinoma, liver transplantation, or death.
The Medical Research Involving Human Subjects Act did not apply to this study. Participation by individual centers was approved at a local level. Patient data were treated anonymously.
HISTOLOGIC EVALUATION
Two expert liver pathologists (J.V., S.H.) scored the liver biopsies in tandem using a multihead microscope with the intention to reach consensus. This was considered the reference diagnosis for evaluation of prognostic value. Liver biopsy sections containing fewer than six evaluable portal tracts were excluded from the study.
The criteria for scoring according to the Nakanuma, Ishak, and Ludwig scoring systems have been described previously (8) (9) (10) (Supporting Tables S1, S2 ). To summarize, both Nakanuma and Ishak scoring systems evaluate disease severity in terms of the histologic grade. The Nakanuma grading system includes degree of cholangitis activity (score 0-3) and hepatitis activity (score 0-3), (9) whereas the Ishak grading system evaluates degree of interface hepatitis (score 0-4), confluent necrosis (score 0-6), lobular inflammation (score 0-4), and portal inflammation (score 0-4) (8) (Supporting Table S1 ).
All three histologic scoring systems evaluate disease progression in terms of stage by scoring the degree of fibrosis (Nakanuma score, 0-3; Ishak score, 0-6; Ludwig score, 0-4). (8) (9) (10) The Nakanuma scoring system additionally scores the degree of bile duct loss (0-3) and deposition of orcein-positive granules (representing copper binding proteins) (0-3). The final Nakanuma stage is obtained from the total score of these three features: stage I (no or minimal progression) corresponds to a score of 0, stage II (mild progression) corresponds to a score of 1-3, stage III (moderate progression) corresponds to a score of 4-6, and stage IV (advanced progression) corresponds to a score of 7-9 (9) (Supporting Table S2 ).
INTEROBSERVER ANALYSIS
A panel of six international expert liver pathologists (J.A., D.W., L.M.W., A.S.H.G., C.S., and V.P.) first attended a tutorial and then participated in a consensus reading, in which 12 cases from the previous Dutch cohort (7) were discussed in the panel using a multihead microscope to clarify uncertainties in terms of grading and staging using the three different scoring systems. Interobserver variability was determined based on scoring of the biopsies on original glass slides (hematoxylin and eosin, connective tissue, and orcein) from the current cohort. All pathologists individually scored all biopsies; no clinical or laboratory data were available to the observers.
ENDPOINTS
Several endpoints were assessed for the time-toevent analyses of association with endpoints. Endpoint 1 was transplant-free survival, defined as a composite of liver transplantation and PSC-related death (death from end-stage liver disease, death from liver surgery, death from cholangiosepsis, and death from cholangiocarcinoma [CCA] ). Although the estimated cumulative risk of developing CCA in PSC amounts to 15% after 20 years, (11) the pathophysiological mechanism leading to CCA in PSC is still to be clarified and may depend partly on the duration and intensity of the chronic inflammation and partly on genetic predisposition of the host. It is uncertain whether death from CCA lies within a biological pathway similar to disease progression in PSC; therefore, death from CCA may not be predicted by liver histology at time of diagnosis. To accommodate for this uncertainty, endpoint 2-liver transplantation-was introduced, which focuses on progression of liver disease only. Endpoint 3, the occurrence of liver-related events at follow-up, was defined as the occurrence of gastroesophageal variceal bleeding, development of ascites, splenomegaly, (12) or hepatic encephalopathy. Ascites and splenomegaly were assessed during yearly surveillance imaging (either abdominal ultrasonography or magnetic resonance cholangiopancreatography). Splenomegaly was defined as a spleen length greater than 120 mm. (12) 
STATISTICAL ANALYSIS
Patient characteristics and laboratory values are expressed as the mean 6 standard deviation or median and interquartile range when having a symmetrical or skewed distribution, respectively. Dichotomous variables were expressed as percentage (%) of the cohort. Reference values of biochemical variables may vary between hospitals and over time; therefore, biochemical variables are expressed as a ratio to the upper or lower limits of normal, as indicated.
Associations of grading and staging with the different clinical endpoints were estimated using a KaplanMeier curve and log-rank test. The potential prognostic value on predicting outcome of clinical, biochemical, and histological variables was assessed using univariable Cox proportional hazards model. Potential multicollinearity between the different staging systems, as well as Mayo risk score and its laboratory components aspartate aminotransferase, albumin, and bilirubin were checked by Spearman's rank correlation coefficient. Using stepwise multivariable Cox proportional hazards regression, the independent predictive value of the histologic scoring systems-entered as continuous variables-was evaluated, from which the hazard ratio (HR) and corresponding 95% confidence interval (CI) could be calculated. The criterion for retaining predictors was P < 0.05.
Interobserver agreement was measured using the multireader linear-weighted Light's kappa index (j), which adjusts for the chance-expected agreement. Additionally, for continuous variables, an intraclass correlation coefficient was calculated. Concordance was qualified according to the arbitrary scale of Landis and Koch (<0.00 5 poor; 0.00-0.20 5 slight; 0.21-0.40 5 fair; 0.41-0.60 5 moderate; 0.61-0.80 5 substantial; >0.81 5 almost perfect agreement). (13) Statistical analyses were performed using SPSS version 22.0 software (SPSS, Chicago, IL); P < 0.05 was considered statistically significant.
Results
PATIENT AND BIOPSY CHARACTERISTICS
We received a total of 154 liver biopsies, 17 of which were excluded due to insufficient amount of portal tracts, poor quality of staining, or an accidental case of sending the wrong tissue biopsy. Of a total of 12 PSC cases, one or more consecutive biopsies were received, of which the first taken biopsy was included in the final cohort. Table 1 summarizes the patient characteristics. A total of 119 patients (corresponding to 119 liver biopsies) were included in the final cohort, of which 81 (68%) were male and 38 (32%) female. The majority of patients (101 [85%]) were diagnosed with large duct PSC, 2 (2%) patients had small duct PSC, and 16 (13%) patients had PSC/AIH-overlap syndrome. Concomitant inflammatory bowel disease was present in 80 (67%) patients. The majority of all 199 patients (68 [57%]) suffered from ulcerative colitis. There was a median follow-up from PSC diagnosis until reaching an endpoint or date of last follow-up of 142 months (interquartile range [IQR] 98-188).
Biopsies had a median of 17 (IQR, 11-24) portal tracts and a median biopsy length of 15 mm (IQR, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The median disease duration at time of biopsy was 0 months (range, 0-38 months). Sixteen (13%) biopsies showed concentric periductal fibrosis, which is characteristic for PSC diagnosis.
PATIENT OUTCOME
During follow-up, 31 (26%) patients died, and 20 (65%) of these 31 deaths were PSC-related. In that subgroup, the median time from PSC diagnosis until PSC-related death was 152 months (IQR, 92-223). Thirty-one (26%) patients underwent liver transplantation, which occurred within a median time of 79 months (IQR, 17-112) from PSC diagnosis. A total of 11 (9%) patients were diagnosed with CCA; for those patients, the median time from diagnosis until developing CCA was 146 months (IQR, 62-224); 8 (73%) patients died.
A total of 35 (29%) patients experienced one or more liver-related events within a median of 85 months (IQR, 14-132) after PSC diagnosis. Seven (6%) patients had a variceal bleed. Ascites occurred in 13 (11%) patients, 18 (15%) patients had an enlarged spleen, and 5 (4%) patients developed hepatic encephalopathy.
DISTRIBUTION OF GRADE AND STAGE
Evaluation of grade and stage according to the three histologic scoring systems was reached by consensus in 100% of cases by the two in tandem scoring pathologists.
Nakanuma grading components cholangitis activity and hepatitis activity were absent in the vast majority of cases, resulting in a median grade of 0 (range, 0-3). The Ishak grading component interface hepatitis was distributed with a median of 1 (range, 0-3), whereas confluent necrosis was only present in four cases, resulting in a median score of 0 (range, 0-6). Degree of lobular inflammation and portal inflammation as scored using the Ishak system revealed a median of 1 (range, 0-4) and 1 (range, 0-3), respectively. Figure  1A ,B illustrates the total Nakanuma and Ishak grades. The distribution of Nakanuma and Ishak grading components is illustrated in Supporting Fig. S1 .
All three histologic components (fibrosis, bile duct loss, and orcein-positive granules) staged using the Nakanuma system were distributed with a median of 1 (range, 0-3), resulting in a median total Nakanuma stage of 2 (range, 1-4) ( Fig. 1C; Supporting Fig. S1 ). The distribution of degree of fibrosis, as scored using the Ishak and Ludwig systems, are shown in 
ASSOCIATION BETWEEN HISTOLOGIC GRADE AND STAGE AND CLINICAL OUTCOME
Kaplan-Meier survivorship estimates indicated a significant association of the Nakanuma stage, Ishak stage, and Ludwig stage with endpoints 1 and 2, the Ishak and Ludwig staging systems were significantly predictive of endpoint 3 ( Fig. 2A-C; Supporting Fig.  S2 ). Table 2 shows the results of the univariable Cox proportional hazard analyses, which were used to analyze potential associations between clinical, biochemical, and histological variables and outcome in PSC, as defined by the three different endpoints. The Ishak and Ludwig staging systems were highly correlated, with a correlation coefficient of 0.93 (P < 0.001). This multicollinearity precluded the analyses of all three staging systems in one multivariable Cox model. Therefore, using stepwise regression, the independence of each individual staging system was assessed by entering each staging system separately. In addition, there was a significant correlation between Mayo risk score and aspartate aminotransferase ratio (correlation coefficient, 0.665; P <0.001), Mayo risk score and bilirubin (correlation coefficient, 0.685; P < 0.001), and Mayo risk score and albumin (correlation coefficient, 20.647; P < 0.001). Therefore, Mayo risk score was not included in multivariable regression analyses.
ENDPOINT 1. COMPOSITE PSC-RELATED DEATH AND LIVER TRANSPLANTATION
Nakanuma grade, Nakanuma stage, Ishak stage, Ludwig stage, center of inclusion, total bilirubin, albumin, platelet count, and Mayo risk score were predictors of endpoint 1 in univariable analysis (Table 2) . Separate multivariable analyses for the three different staging systems showed that the Nakanuma grading system was inversely associated with endpoint 1 (corrected for Ishak stage: HR, 0.55 [95% CI, 0.31-0.99], P 5 0.046; corrected for Ludwig stage: HR, 0.54 [95% CI, 0.30-0.98], P 5 0.041). Each incremental grade corresponds to a 55% and 54% decreased risk, respectively, of reaching an endpoint. In contrast, the Nakanuma staging system was positively associated with endpoint 1 (HR, 2.14 (95% CI, 1.22-3.77), P 5 0.008) ( Table 3) .
ENDPOINT 2. LIVER TRANSPLANTATION
The same predictors of endpoint 1 were shown to be associated with endpoint 2 in univariable Cox regression analysis ( All data are presented as HR (95% CI). The independent prognostic value of the individual staging systems was assessed by stepwise regression. 
ENDPOINT 3. LIVER RELATED EVENTS
The variables Nakanuma stage, Ishak stage, Ludwig stage, age at diagnosis PSC, coexisting inflammatory bowel disease, center of inclusion, total bilirubin, and Mayo risk score were significant predictors for the occurrence of liver-related events in univariable analysis ( Table 2 ). The Nakanuma, Ishak, and Ludwig staging systems were all shown to be independently associated with the occurrence of liver-related events on multivariable analyses (Nakanuma: 
MULTIVARIABLE ANALYSIS NAKANUMA STAGING COMPONENTS
When analyzing the prognostic value of the individual Nakanuma staging components to predict endpoints 1, 2, and 3, orcein deposition was shown to be the strongest independent predictor (HR, 
INTEROBSERVER AGREEMENT
A 2-day time frame allowed for a total of 76 biopsies to be scored by each of the six participating pathologists. One case was excluded due to a difference in cutting depth between stainings within the same case, which caused a variation in staging and grading among different slides. In two cases, no orcein staining was available; therefore, they were excluded from the analysis for orcein-positive granules and Nakanuma total stage.
The interobserver agreement for Nakanuma grade and stage, Ishak grade and stage, and Ludwig stage is shown in Table 5 . Interobserver agreement was moderate for Nakanuma stage (j 5 0.56) and was substantial for both Ishak and Ludwig stage (j 5 0.64 and j 5 0.62, respectively). Interobserver agreement was highest for the fibrosis component of Nakanuma staging, compared with both bile duct loss and deposition of orcein-positive granules (j 5 0.67, j 5 0.47, and j 5 0.58, respectively). Nakanuma grade showed moderate agreement (j 5 0.43), and Ishak grade using 
Discussion
This study confirms the prognostic value and demonstrates for the first time reproducibility of disease staging using the Nakanuma, Ishak, and Ludwig staging systems.
We demonstrated that all three staging systems were predictors of liver transplantation and development of liver cirrhosis-related events. In contrast, the Ishak and Ludwig scoring systems were not independent predictors of endpoint 1 (composite PSC-related death and liver transplantation). The inclusion of death from CCA in endpoint 1-which may not be predictable by histology-could have contributed to this difference. Additional univariable analysis showed that, indeed, neither grading nor staging liver histology were of prognostic importance for the development of CCA (Supporting Table S3 ).
In accordance with the previous study on the prognostic value of histology in PSC, (7) we found that the Nakanuma staging system was the strongest histological predictor of long-term clinical outcomes. This is in concordance with study results in PBC, where the Nakanuma staging system was repeatedly shown to be superior to the classical Ludwig and Scheuer staging systems in predicting clinical outcome. (14, 15) These observations may be explained by the inclusion of three staging components that reflect histopathological progression of liver injury in vanishing bile duct diseases. (15) Of the individual staging components, orcein deposition was, as also shown in the previous study, the most valuable histologic predictor. (7) In addition, the degree of orcein deposition was strongly correlated with alkaline phosphatase-an important prognostic biochemical marker in PSC (16) (Supporting Table S4 ). These results are in concordance with the recent findings in PBC of both Kakuda et al. (14) and Chan et al., (15) who demonstrated that the copper binding protein score was the most powerful histologic prognostic Nakanuma staging component. The deposition of orcein-positive granules is a sensitive marker of chronic cholestasis in the liver, (17) most likely related to the inability to excrete copper-associated protein in bile due to bile duct loss. The accumulation of copperassociated protein in periportal hepatocytes is frequently associated with other morphological changes related to the accumulation of toxic bile acids, such as hepatocyte ballooning and Mallory-Denk body formation ("cholate stasis"), and may thus be an important marker of disease progression in PSC. (5) The interobserver variability assessment of orcein-positive granules showed moderate agreement (j 5 0.58), which is comparable with the agreement observed in the study by Nakanuma et al. (9) (j 5 0.41). Although bile duct loss might theoretically be a more sensitive marker of disease progression in ductopenic diseases such as PSC, loss of bile ducts is often patchy in distribution and may thus be subject to problems with sampling variability in liver biopsy specimens. The absence of an association between degree of bile duct loss and clinical outcomes was therefore not surprising, and similar results were reported in a previous study by de Vries et al. (7) Of all three Nakanuma staging components, bile duct loss showed the lowest agreement (j 5 0.47). In a previous study by Wendum et al., (18) interobserver agreement of bile duct loss in liver biopsies of PBC patients increased from moderate to substantial by adding keratin 7 immunostaining. We chose to use hematoxylin and eosin staining for the evaluation of bile duct loss in the present study to obtain the best replicate of the original scoring system by Nakanuma et al. (9) Adding a keratin 7 staining may, however, improve performance. Unfortunately, our study was insufficiently powered to assess the independent prognostic value of the individual Nakanuma staging components in a multivariable model, which also included clinical and biochemical parameters.
Similar to what has been demonstrated in PBC, we found no association between Nakanuma grade and liver-related events. (14, 15) There was, however, an unexpected negative association between Nakanuma grade and the composite endpoint 1 and endpoint 2, a higher Nakanuma grade being associated with a decreased possibility of reaching these endpoints. This difference could not be explained by the inclusion of PSC/AIH patients, who would be expected to have relatively high scores for the degree of hepatitis activity, because the prognostic value of Nakanuma grade was driven by the cholangitis activity component (Table 2) . We investigated whether Nakanuma grade could reflect an early (inflammatory) disease stage and a corresponding better prognosis, with less fibrosis by assessing the association between cholangitis activity and degree of fibrosis, but no such association was found (Supporting Table S5 ). Overall, cholangitis activity and hepatitis activity are not prominent features in PSC and were present in only 27% versus 14% of cases, respectively. The resulting limited sample size per grade is important to take into consideration, and the negative association between Nakanuma grade and outcome should therefore be interpreted with caution. Compared with the slight agreement for cholangitis activity and hepatitis activity observed in PBC (j 5 0.110, j 5 0.197, respectively), (9) in our study agreement was much higher, yielding fair and moderate agreement, respectively ( Table 5 ). The low agreement by Nakanuma et al. (9) was thought to be due to differences in assessment processes in different institutions. The consensus reading that took place before scoring may have added to the improved agreement within the present study. Furthermore, the majority of reviewers in the panel in Nakanuma's study consisted of nonexpert liver pathologists. (9) The proportion of PSC/AIH-overlap patients (13%) included in the present study was relatively high when compared with the 4%-7% reported in large epidemiologic studies. (11, 19) PSC/AIH-overlap may be regarded as a distinct disease entity, with an altered prognosis. (20, 21) A sensitivity analysis in which PSC/ AIH-overlap patients were excluded was performed to assess the potential impact of PSC/AIH-overlap on the prognostic value of the histologic scoring systems. No differences were found (data not shown). Moreover, the independent association of all three histologic staging systems with outcome confirms the applicability of liver histology as a risk stratifier in PSC. Carbone at al. (22) recently reported a similar independent association between degree of fibrosis and long-term outcome in PBC. Through risk stratification (into low/ high risk for poor outcome) patient subgroups that potentially have the greatest benefit from inclusion and treatment in clinical trials may be identified using their initial liver biopsy. (4) The patchy distribution of the PSC liver carries the risk of sampling variability in PSC biopsies. (23, 24) In addition, the use of liver biopsy is hampered by its invasive nature and interpretative inconsistencies. The correlation of histology with clinical outcomes in the present study suggests that sampling variability when it comes to staging is not a significant issue in the context of using liver biopsy findings as surrogate endpoints in clinical trials. Furthermore, interobserver reproducibility regarding staging was shown to be moderate, where disagreement of more than one stage was not observed. Repeated biopsies were present in a small subset of PSC cases (n 5 12), of which orcein staining was missing in one case. A subanalysis of the remaining 11 cases showed progression of Nakanuma stage in five cases, steady status in five cases, and regression in one case (data not shown). There was a trend for worsening of Nakanuma stage over time (P 5 0.096), which may be due to the limited number of samples.
The development of liver fibrosis and the end stage of liver cirrhosis were long thought to be unidirectional and irreversible. However, increased understanding of the pathophysiology of hepatic fibrogenesis-especially in the field of chronic viral hepatitis and autoimmune hepatitis-has revealed that this is a dynamic process that can be prevented or reversed by either eliminating the etiologic agent or intervening with the pathogenic mechanism. (25) (26) (27) Further research is necessary to assess whether treatment effects could be measured by a change in histologic stage. If this would be the case, this would warrant further study of the use of liver histology as a potential surrogate endpoint in clinical trials.
Although the Ludwig staging system is the most commonly used staging system in PSC, to our knowledge, no interobserver studies have been performed to assess interrater variability in scoring of PSC biopsies. For other liver diseases, interrater reliability using Ludwig's and Ishak's staging systems showed fair and substantial agreement (j 5 0.32 in PBC and j 5 0.61 in HCV respectively), (18, 28) whereas both staging systems showed substantial agreement in the present study regarding PSC. Because PSC is a rare disease, often requiring tertiary care, only expert liver pathologists were invited to participate in our interobserver study, which may explain these differences. Two of the grading criteria (Nakanuma's cholangitis activity and Ishak's confluent necrosis) showed only fair agreement. The former may be explained by its low frequency in the sample set; for the latter, this was due to a structural difference in interpretation by one rater. However, because confluent necrosis in this study and the previous study (7) did not correlate with prognosis, this deviation was deemed irrelevant. All other scoring components showed moderate or substantial agreement, implicating that scoring liver biopsies using the Nakanuma, Ishak, and Ludwig systems is reproducible in PSC, especially regarding staging. Furthermore, these kappa values compare favorably with what is described for histological variability in various other liver diseases as reviewed by Goodman. (29) In case of using these scoring systems in clinical trials, variability limitations may be overcome through expertise and scoring the biopsies in consensus.
Promising noninvasive modalities such as enhanced liver fibrosis score and transient elastography may be a future substitute for the measure of fibrosis. (30, 31) However, the value of liver histology in PSC is not restricted to staging liver fibrosis, and the important additional prognostic value of staging the degree of orcein deposition currently cannot be replaced by noninvasive tools. An additional advantage of liver histology is that it measures disease progression within the affected organ itself and has the potential advantage of construct validity. Furthermore, it allows for mechanistic studies to investigate the effect of an investigational drug. (4, 32) This study has several limitations. First, because not all PSC patients routinely undergo liver biopsy, and because this was a retrospective accrual of cases, selection bias of patients cannot be excluded. Second, the development of liver-related events has not been systematically assessed, but rather has relied on clinicianreported incidence that may yield an underestimation. Finally, because the recently presented novel prognostic model for PSC (de Vries et al., unpublished data)-including biochemistry values at time of diagnosisshowed adequate performance in predicting prognosis in PSC, we decided to use available biochemistry values at time of diagnosis for the multivariable regression analyses. However, biochemistry results at time of diagnosis may differ from the results at time of biopsy, because not all biopsies were taken at the time of diagnosis. A potential limitation of the liver histologic staging systems overall is that they may have no prognostic value for development of CCA, which is a significant cause of morbidity and death of PSC patients.
In conclusion, the histologic staging systems developed by Nakanuma, Ishak, and Ludwig were confirmed to be independent predictors of long-term outcome in PSC, in this multicenter cohort. The Nakanuma staging system, which incorporates bile duct loss and orcein deposition as features of chronic biliary disease, was shown to hold the strongest predictive value as well as adequate reproducibility and may therefore be considered the preferred system for scoring PSC liver biopsies. Histologic scoring may be a useful tool for risk stratification and may be explored as surrogate endpoint in clinical trials of PSC.
